Skip to main content
OpenTrials
Completed

NCT Number: NCT06702436

Invasive vs. Conservative Management in Cancer Patients With Non-ST Elevation MI (CAN-NSTEMI)"

This retrospective study investigates the impact of invasive versus conservative management strategies in cancer patients presenting with non-ST elevation myocardial infarction (non-ST MI). Patients aged 18 and older, who were treated for non-ST MI in a hospital setting and had a confirmed cancer diagnosis, are included. The primary outcome is hospital mortality, assessed using GRACE scores to evaluate mortality risk. Patients are grouped based on their received interventions-either invasive (including coronary angiography and revascularization) or pharmacological treatment. Risk factors contributing to mortality, such as cancer type, metastasis presence, comorbidities, and laboratory findings, will also be analyzed to better understand the interplay of oncologic and cardiovascular conditions in this population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myocardial Infarction Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Ischemia Necrosis Neoplasms Non-ST Elevated Myocardial Infarction Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara Oncology Training and Research Hospital

Ankara, 06200, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: Patients aged 18 years and older.
  • Diagnosis: Patients with a confirmed cancer diagnosis.
  • Acute Condition: Patients diagnosed with non-ST elevation myocardial infarction (non-ST MI).
  • Treatment: Patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-ST MI.
  • Consent: Patients who have provided informed consent or are part of a retrospective study where consent is waived.

Exclusion criteria

  • Age: Patients younger than 18 years.
  • Non-cancer diagnoses: Patients without a cancer diagnosis.
  • ST-Elevation Myocardial Infarction: Patients with ST elevation myocardial infarction (STEMI) instead of non-ST elevation myocardial infarction (NSTEMI).
  • Pre-existing severe comorbidities: Patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes.
  • Incomplete medical records: Patients with missing data on relevant clinical variables (e.g., GRACE score, treatment received, or mortality data).
  • Pregnancy: Pregnant patients, as their conditions may complicate the interpretation of results.
  • Inability to provide informed consent: Patients unable to provide informed consent (if applicable).

Treatment and study plan

observational study

Other

This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians

Primary outcomes

  1. hospital mortality

    Time frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 30 days.

    Hospital mortality rate in cancer patients with non-ST elevation myocardial infarction, comparing invasive and conservative treatment strategies

Secondary outcomes

  1. Length of hospital stay:

    Time frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 100 days.

    Comparison of the duration of hospitalization between the invasive treatment group and the conservative treatment group.

  2. Re-hospitalization rate

    Time frame: The time frame for assessing re-hospitalization is from the date of hospital discharge to 100 days post-discharge

    Rate of readmission after initial discharge, comparing the two treatment strategies.

Sponsors and collaborators

Lead sponsor

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Other

Registry information

Official study title

Impact of Treatment Approaches on Mortality in Cancer Patients With Non-ST Elevation Myocardial Infarction: Invasive vs. Conservative Strategies

Acronym: CAN-NSTEMI

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Nov 25, 2024
Registry last updated
Sep 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.